CD24+/CD38- as new prognostic marker for non-small cell lung cancer
Tóm tắt
Lung cancer is the leading cause of death among cancers in the world. The annual death toll due to this disease exceeds the combined deaths caused by colon, breast, prostate, and pancreatic cancers. As a result, there has been a tremendous effort to identify new biomarkers for early detection and diagnosis of lung cancer. In this study we report the results of screening a panel of eight non-small cell lung cancer (NSCLC) cell lines originating from different subtypes of lung cancer in an attempt to identify potential biomarkers unique to this disease. We used real-time polymerase chain reaction and flow cytometry techniques to analyze the expression of ALDHA1, EpCAM, CD133, CD24, and CD38 in this panel. We demonstrate for the first time that the majority of NSCLC cells do not express levels of CD38 that would qualify it as a new biomarker for the disease. In contrast, we found that CD24 is over-expressed in 6 out of 8 of the cell lines. The combined CD24+/CD38-/low phenotype was detected in 50% of the cell lines that are also positive for CD133 and EpCAM. We report that CD24+/CD38-/low signature could potentially be used as a new biomarker for the early detection of NSCLC.
Tài liệu tham khảo
Cagle PT, Chirieac LR: Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med. 2012, 136: 504-509. 10.5858/arpa.2011-0618-RA.
Woodward RM, Brown ML, Stewart ST, Cronin KA, Cutler DM: The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF. Cancer. 2007, 110: 2511-2518. 10.1002/cncr.23058.
Cipriano LE, Romanus D, Earle CC, Neville BA, Halpern EF, Gazelle GS, McMahon PM: Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value Health. 2011, 14: 41-52. 10.1016/j.jval.2010.10.006.
Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP: Epigenetic biomarkers in lung cancer. Cancer Lett. 2012, Apr 27. [Epub ahead of print]
Kristiansen G, Schlüns K, Yongwei Y, Denkert C, Dietel M, Petersen I: CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer. 2003, 88: 231-236. 10.1038/sj.bjc.6600702.
Spiro SG, Tanner NT, Silvestri GA, Janes SM, Lim E, Vansteenkiste JF, Pirker R: Lung cancer: progress in diagnosis, staging and therapy. Respirology. 2010, 15: 44-50. 10.1111/j.1440-1843.2009.01674.x.
Chen HY, Yu SL, Li KC, Yang PC: Biomarkers and transcriptome profiling of lung cancer. Respirology. 2012, 17: 620-626. 10.1111/j.1440-1843.2012.02154.x.
Leng S, Do K, Yingling CM, Picchi MA, Wolf HJ, Kennedy TC, Feser WJ, Baron AE, Franklin WA, Brock MV, Herman JG, Baylin SB, Byers T, Stidley CA, Belinsky SA: Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin Cancer Res. 2012, 18: 3387-3395. 10.1158/1078-0432.CCR-11-3049.
Gámez-Pozo A, Sánchez-Navarro I, Calvo E, Agulló-Ortuño MT, López-Vacas R, Díaz E, Camafeita E, Nistal M, Madero R, Espinosa E, López JA, Fresno Vara JÁ: MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics. PLoS One. 2012, 7: e33752-10.1371/journal.pone.0033752.
Moreb JS, Zucali JR, Ostmark B, Benson NA: Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by Aldefluor flow cytometry-based assay. Cytometry B Clin Cytom. 2007, 72: 281-289.
Vasiliou V, Pappa A, Petersen DR: Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact. 2000, 129: 1-19. 10.1016/S0009-2797(00)00211-8.
Moreb JS, Baker HV, Chang LJ, Amaya M, Lopez MC, Ostmark B, Chou W: ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer. 2008, 7: 87-10.1186/1476-4598-7-87.
Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R, Gray BA, Moreb JS: Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact. 2009, 178: 48-55. 10.1016/j.cbi.2008.09.029.
Pak MG, Shin DH, Lee CH, Lee MK: Significance of EpCAM and TROP2 expression in non-small cell lung cancer. World J Surg Oncol. 2012, 6: 10-53.
van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG: EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis. 2010, 31: 1913-1921. 10.1093/carcin/bgq187.
Munz M, Baeuerle PA, Gires O: The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009, 69: 5627-5629. 10.1158/0008-5472.CAN-09-0654.
Akunuru S, James Zhai Q, Zheng Y: Non-small cell lung cancer stem/progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity. Cell Death Dis. 2012, 3: e352-10.1038/cddis.2012.93.
Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF: CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 2008, 99: 100-109. 10.1038/sj.bjc.6604437.
Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M, Yamamoto T, Rino Y, Kitamura H, Masuda M: Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol. 2010, 4: 32-42.
Kristiansen G, Sammar M, Altevogt P: Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol. 2004, 35: 255-262.
Karimi-Busheri F, Rasouli-Nia A, Mackey JR, Weinfeld M: Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res. 2010, 2: R31.
Karimi-Busheri F, Zadorozhny V, Shawler DL, Fakhrai H: The stability of breast cancer progenitor cells during cryopreservation: maintenance of proliferation, self-renewal, and senescence characteristics. Cryobiology. 2010, 60: 308-314. 10.1016/j.cryobiol.2010.02.005.
Karimi-Busheri F, Zadorozhny V, Li T, Lin H, Shawler DL, Fakhrai H: Pivotal role of CD38 biomarker in combination with CD24, EpCAM, and ALDH for identification of H460 derived lung cancer stem cells. J Stem Cells. 2011, 6: 9-20.
Karimi-Busheri F, Zadorozhny V, Carrier E, Fakhrai H: Molecular integrity and global gene expression of breast and lung cancer stem cells under long-term storage and recovery. Cell Tissue Bank. 2013, 14: 175-186. 10.1007/s10561-012-9315-3.
Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N: CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011, 118: 3470-3478. 10.1182/blood-2011-06-275610.
Hamblin TJ: CD38: what is it there for?. Blood. 2003, 102: 1939-1940. 10.1182/blood-2003-07-2231.
Jawad M, Yu N, Seedhouse CH, Tandon K, Russell NH, Pallis M: Targeting of CD34 + CD38- cells using Gemtuzumab Ozogamicin (Mylotarg) in combination with Tipifarnib (Zarnestra) in Acute Myeloid Leukaemia. BMC Cancer. 2012, 12: 431-10.1186/1471-2407-12-431.
Dürig J, Naschar M, Schmücker U, Renzing-Köhler K, Hölter T, Hüttmann A, Dührsen U: CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia. 2002, 16: 30-35. 10.1038/sj.leu.2402339.
Sugarbaker DJ, Dasilva MC: Diagnostic workup of lung cancer. Surg Oncol Clin N Am. 2011, 20: 667-679. 10.1016/j.soc.2011.08.003.
Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD: Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst. 2010, 102: 1310-1321. 10.1093/jnci/djq279.
Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, Burkett MW, Hite KM, Alley M, Hollingshead M, Shoemaker RH, Niederhuber JE: Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells. 2010, 28: 649-660. 10.1002/stem.324.
Shoemaker RH: The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006, 6: 813-823.
Ni J, Cozzi PJ, Duan W, Shigdar S, Graham PH, John KH, Li Y: Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer Metastasis Rev. 2012, 31: 779-791. 10.1007/s10555-012-9389-1.
Nordgård O, Singh G, Solberg S, Jørgensen L, Halvorsen AR, Smaaland R, Brustugun OT, Helland A: Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer. PLoS One. 2013, 8: e62153-10.1371/journal.pone.0062153.
Vroling L, Lind JS, de Haas RR, Verheul HM, van Hinsbergh VW, Broxterman HJ, Smit EF: CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. Br J Cancer. 2010, 102: 268-275. 10.1038/sj.bjc.6605477.
Mierke CT, Bretz N, Altevogt P: Contractile forces contribute to increased glycosylphosphatidylinositol-anchored receptor CD24-facilitated cancer cell invasion. J Biol Chem. 2011, 286: 34858-34871. 10.1074/jbc.M111.245183.
Lee HJ, Choe G, Jheon S, Sung SW, Lee CT, Chung JH: CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. J Thorac Oncol. 2010, 5: 649-657.
Deaglio S, Vaisitti T, Serra S, Audrito V, Bologna C, DAQZAZ’Arena G, Laurenti L, Gottardi D, Malavasi F: CD38 in chronic lymphocytic leukemia: from bench to bedside?. Mini Rev Med Chem. 2011, 11: 503-507. 10.2174/138955711795843338.